Latest News on ISRG

Financial News Based On Company


Advertisement
Advertisement

Form 4 Intuitive Surgical Inc: Mark Brosius (EVP & Chief Mfg and Supply Cha) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-intuitive-surgical-inc-mark-brosius-evp--chief-mfg-and-supply-cha-for-16-november-93CH-5713765
This article reports on a Form 4 filing for Intuitive Surgical Inc., indicating that Mark Brosius, EVP & Chief Mfg and Supply Chain, was involved in a transaction on November 16. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by insiders. The filing likely details the specifics of stock transactions by the executive.

Intuitive Surgical evp Mark Brosius sells $60,367 in shares By Investing.com

https://ca.investing.com/news/stock-market-news/intuitive-surgical-evp-mark-brosius-sells-60367-in-shares-93CH-4968156
Mark Brosius, EVP at Intuitive Surgical Inc. (NASDAQ:ISRG), sold shares worth $60,367 over three days in November 2026, as part of a pre-arranged trading plan. The sales occurred while the company reported 20% revenue growth and received several upward revisions to earnings estimates from analysts. Despite a recent litigation settlement affecting GAAP EPS, analysts generally maintain positive outlooks for Intuitive Surgical, noting strong procedure growth and da Vinci system placements.

Over three days, an Intuitive Surgical (ISRG) executive sold 46 shares a day, for 138 in all.

https://www.stocktitan.net/sec-filings/ISRG/form-4-intuitive-surgical-inc-insider-trading-activity-72ee834d05cc.html
Mark Brosius, Executive Vice President and Chief Manufacturing and Supply Chain Officer at Intuitive Surgical Inc. (ISRG), sold a total of 138 common shares over three days: November 16, 17, and 18, 2026. Each day, he sold 46 shares at varying prices ($444.38, $437.33, and $430.63, respectively) under a Rule 10b5-1 trading plan. After these transactions, Brosius directly holds 319 shares of common stock.

GE HealthCare Expands Global Research Network for Photon-Counting CT

https://www.tradingview.com/news/zacks:6158e7bf6094b:0-ge-healthcare-expands-global-research-network-for-photon-counting-ct/
GE HealthCare has expanded its global research network for its Photonova Spectra photon-counting CT system, collaborating with seven leading institutions in North America, Europe, and Asia. This initiative follows regulatory clearances and aims to generate clinical evidence across various applications, enhancing diagnostic capabilities and supporting early disease detection. The move is expected to strengthen GE HealthCare's position in the advanced medical imaging market, with the global photon-counting CT market projected for significant growth.

Should You Continue to Hold Charles River Stock in Your Portfolio?

https://www.tradingview.com/news/zacks:fac182df8094b:0-should-you-continue-to-hold-charles-river-stock-in-your-portfolio/
Charles River Laboratories International (CRL) is experiencing improving demand, bookings, and backlog in its Discovery and Safety Assessment (DSA) segment, along with a strong solvency position, which supports its growth. However, the company faces competitive pressures and unfavorable foreign exchange rates that could impact its performance. The article recommends a "Hold" rating for CRL stock due to these mixed factors.
Advertisement

BTIG maintains Intuitive Surgical at Buy, raises price target to $513 from $454

https://www.tradingview.com/news/tradingview:00cf4463f2152:0-btig-maintains-intuitive-surgical-at-buy-raises-price-target-to-513-from-454/
BTIG has maintained its "Buy" rating on Intuitive Surgical (ISRG) and increased its price target to $513 from $454, representing a 13.0% hike. This new price target suggests a 19.2% upside from the stock's closing price of $430.53 on November 17. The article also notes recent analyst actions from other firms, with price targets ranging from $385 to $503.

Here's Why You Should Add GEHC Stock to Your Portfolio Right Now

https://www.theglobeandmail.com/investing/markets/stocks/ISRG-Q/pressreleases/8877397/here-s-why-you-should-add-gehc-stock-to-your-portfolio-right-now/
GE HealthCare Technologies, Inc. (GEHC) is a Zacks Rank #2 (Buy) company poised for growth due to strong order momentum, a record backlog, and strength in its Pharmaceutical Diagnostics business, as well as an expanding pipeline of AI-enabled innovations. Despite potential headwinds from inflationary pressures and tariff uncertainty, the company's operational recovery in Patient Care Solutions and new product innovations are expected to drive revenue and margin expansion. Analyst estimates show a positive revision trend for 2026, with anticipated increases in revenue and EPS.

Ecolab Launches Integrated Cooling Platform to Tap AI Growth

https://www.tradingview.com/news/zacks:bb44ecc7c094b:0-ecolab-launches-integrated-cooling-platform-to-tap-ai-growth/
Ecolab recently introduced an integrated cooling platform designed for AI data centers, aiming to enhance computing performance and improve water and energy efficiency. The platform combines CoolIT's direct liquid cooling hardware with Ecolab's fluid management expertise and digital technology, including 3D TRASAR. This initiative is expected to strengthen Ecolab's position in the rapidly expanding AI infrastructure market, supporting its goal of reaching $4 billion in High-Tech sales by 2030.

Medtronic’s Hugo robot gets expanded FDA clearance in general surgery

https://www.medtechdive.com/news/medtronics-hugo-robot-gets-expanded-fda-clearance-in-general-surgery/874904/
Medtronic's Hugo robotic surgery system has received expanded FDA clearance for use in general surgery procedures, including upper and lower abdominal surgeries. This clearance significantly broadens Hugo's market reach, covering over half of the soft tissue procedures performed annually in the U.S. Medtronic aims to leverage its existing expertise in general surgery to further penetrate the robotic surgery market, where it is experiencing rapid global growth with its Hugo system.

Here's Why You Should Add GEHC Stock to Your Portfolio Right Now

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8877395/heres-why-you-should-add-gehc-stock-to-your-portfolio-right-now/
GE HealthCare Technologies, Inc. (GEHC) is identified as a strong buy due to its record backlog, robust order momentum, and growth in its Pharmaceutical Diagnostics business, coupled with an expanding pipeline of AI-enabled innovations. Despite facing risks from inflationary pressures and tariff uncertainties, the company shows promising operational recovery in Patient Care Solutions and strong new product innovation. Management has also raised its full-year adjusted EBIT margin and EPS outlook, reflecting confidence in sustained operational improvements.
Advertisement

Medtronic gets FDA clearance for Hugo general surgery

https://mugglehead.com/medtronic-hugo-fda-clearance-general-surgery/
Medtronic (NYSE: MDT) has received FDA clearance for its Hugo robotic surgery system to be used in general surgery, expanding its application beyond urology. This expanded indication covers approximately 3.5 million procedures annually in the U.S., including various upper and lower-abdominal surgeries. The company expects worldwide Hugo procedures to exceed 50,000 by its fiscal year-end, signaling significant growth potential in the competitive robotic surgery market.

ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?

https://www.tradingview.com/news/zacks:27ed14d4d094b:0-isrg-eps-climbs-25-to-3-is-innovation-driving-profitable-growth/
Intuitive Surgical (ISRG) reported strong adjusted earnings growth in Q3 2026, with EPS up 25% to $3 and revenue increasing 22% to over $3 billion, driven by the adoption of its robotic platforms and improved operating efficiency. The company continues to invest heavily in innovation, including AI capabilities for its da Vinci 5 system and new instrumentation, which is reflected in increased R&D expenses. While adjusted profit rose significantly, GAAP net income declined due to a $450 million litigation settlement.

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

https://news.medtronic.com/2026-11-17-Medtronic-announces-FDA-clearance-of-general-surgery-procedures-for-the-Hugo-TM-robotic-assisted-surgery-RAS-system
Medtronic plc has announced that its Hugo™ robotic-assisted surgery (RAS) system has received FDA clearance for use in general surgery procedures. This expanded clearance includes upper and lower abdominal procedures, covering a significant portion of all soft-tissue surgeries performed annually in the U.S. The move aims to provide hospitals with more flexibility in addressing capacity challenges and offering advanced surgical options to patients.

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assisted-surgery-ras-system-302941366.html
Medtronic plc announced that its Hugo™ robotic-assisted surgery (RAS) system has received U.S. FDA clearance for use in general surgery procedures, expanding its application beyond urology. This clearance covers a wide range of upper and lower abdominal procedures, which account for over half of all soft-tissue surgeries annually in the U.S. The Hugo RAS system's modular design and integration with Medtronic technologies like the LigaSure™ RAS Maryland instrument aim to provide greater flexibility and accessibility for surgical teams and patients.

LivaNova at Jefferies conference: growth plan spans core units and sleep apnea

https://www.investing.com/news/transcripts/livanova-at-jefferies-conference-growth-plan-spans-core-units-and-sleep-apnea-93CH-5032184
LivaNova outlined its growth strategy at the Jefferies Global Healthcare Conference, focusing on sustained expansion in its cardiopulmonary and epilepsy businesses, alongside significant investments in new markets like sleep apnea and depression. The company upgraded its full-year growth outlook to 9-10% and detailed a two-phase margin plan, aiming for mid-20s operating margins by 2030 as new ventures scale. Key innovations include a next-generation epilepsy implant, a differentiated sleep apnea treatment, and upgraded cardiopulmonary products.
Advertisement

Medtronic Targets Stroke Prevention Technologies in $380 Million Contego Deal

https://www.tradingview.com/news/benzinga:bf1fd45e4094b:0-medtronic-targets-stroke-prevention-technologies-in-380-million-contego-deal/
Medtronic announced its intention to acquire Contego Medical for $380 million, expanding its offerings in carotid artery disease and peripheral thrombectomy. This acquisition includes Contego’s FDA-approved Neuroguard IEP Direct System for transcarotid artery revascularization and Excipio thrombectomy devices. Medtronic expects the deal to minimally dilute adjusted earnings per share in fiscal years 2027 and 2028 before becoming accretive.

Intuitive Surgical Inc. stock underperforms Monday when compared to competitors

https://www.marketwatch.com/data-news/intuitive-surgical-inc-stock-underperforms-monday-when-compared-to-competitors-1f128b34-3490aaf221a8?mod=goog_fin_scmw
Intuitive Surgical Inc. (ISRG) stock fell 1.32% on Monday to $437.75, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. The company's shares closed 27.51% below their 52-week high of $603.88, achieved earlier in the year.

Precision Optics Reports First Quarter Fiscal 2027 Financial Results

https://www.globenewswire.com/news-release/2026/11/16/3404160/34800/en/precision-optics-reports-first-quarter-fiscal-2027-financial-results.html
Precision Optics Corporation (Nasdaq: POCI) announced strong financial results for its first quarter of fiscal 2027, with revenue increasing 22% year-over-year to $8.2 million and gross margin improving to 22.5%. The company narrowed its net loss and saw significant contributions from its satellite optical communications and single-use medical device programs, leading to reaffirmed fiscal year 2027 revenue guidance of $30 million to $33 million.

Here's Why You Should Retain PHG Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:aeb3130a9094b:0-here-s-why-you-should-retain-phg-stock-in-your-portfolio-for-now/
Koninklijke Philips (PHG) is positioned for growth due to strong order momentum in its imaging, image-guided therapy, and monitoring platforms, along with innovation in Personal Health products. Despite challenges like ultrasound manufacturing delays, pricing pressure from China, and inflation, the company's equipment order intake, broad-based growth in Personal Health, and increasing adoption of Monitoring-as-a-Service indicate positive prospects. Analysts maintain a "Hold" rating, and the stock has outperformed the industry year-to-date.

SS Innovations International (NASDAQ: SSII) Promotes Vishwa Srivastava to President, Appoints Gary Lo CFO

https://www.usatoday.com/press-release/story/58366/ss-innovations-international-nasdaq-ssii-promotes-vishwa-srivastava-to-president-appoints-gary-lo-cfo/
SS Innovations International (NASDAQ: SSII) has announced the promotion of Dr. Vishwa Srivastava to President and the appointment of Gary Lo as Chief Financial Officer. Dr. Srivastava will focus on building the company's U.S. business and leading global operations, while Mr. Lo brings extensive financial leadership experience. These changes support SS Innovations' international expansion plans for its SSi Mantra surgical robotic system and the development of new healthcare technologies.
Advertisement

CONMED at Jefferies Global Healthcare Conference: growth drivers build By Investing.com

https://ca.investing.com/news/stock-market-news/conmed-at-jefferies-global-healthcare-conference-growth-drivers-build-93CH-4960412
CONMED Corporation outlined its business strategy at the Jefferies Global Healthcare Conference, emphasizing steady growth driven by stable demand in core markets, strong adoption of key products like AirSeal and Buffalo Filter, and new legislative support for smoke evacuation. The company expects mid-single-digit revenue growth and approximately 10% EPS growth, but anticipates cost pressures from raw materials and freight in 2027. Management also discussed the transition period for BioBrace in the U.S. and its M&A strategy, aiming for further deleveraging while considering acquisitions in general surgery and orthopedics.

Alberta Investment Management Corp Purchases 252,106 Shares of Zimmer Biomet Holdings, Inc. $ZBH

https://www.marketbeat.com/instant-alerts/filing-alberta-investment-management-corp-purchases-252106-shares-of-zimmer-biomet-holdings-inc-zbh-2026-11-16/
Alberta Investment Management Corp significantly increased its stake in Zimmer Biomet Holdings, Inc. by 84.6% during the third quarter, acquiring an additional 252,106 shares. This brings their total holdings to 550,000 shares, valued at approximately $48.9 million. The company recently exceeded quarterly earnings and revenue expectations and maintains a consensus "Hold" rating from analysts with an average price target of $112.74.

Form 4 Intuitive Surgical Inc: Fredrik Widman (VP Corporate Controller) For: 15 September

https://au.investing.com/news/stock-market-news/form-4-intuitive-surgical-inc-fredrik-widman-vp-corporate-controller-for-15-september-93CH-4771756
This article reports on a Form 4 filing for Intuitive Surgical Inc., detailing an insider transaction by Fredrik Widman, the VP Corporate Controller, on September 15. Form 4 filings are regulatory documents disclosing changes in ownership of company stock by insiders. The article also provides the stock symbol ISRG and mentions its current performance.

Form 144 Intuitive Surgical For: 15 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-intuitive-surgical-for-15-november-93CH-2808694
This article from Investing.com announces the filing of Form 144 for Intuitive Surgical (ISRG) on November 15, 2026. Form 144 is a notice of the intent to sell restricted securities. The article provides the title and date, along with the stock symbol and its minor price change for the day.

Where Will Intuitive Surgical Be in 10 Years? Hint: Its da Vinci 5 Installed Base Just Topped 2,000

https://www.theglobeandmail.com/investing/markets/stocks/ISRG/pressreleases/8845679/where-will-intuitive-surgical-be-in-10-years-hint-its-da-vinci-5-installed-base-just-topped-2000/
Intuitive Surgical, a leader in robotic-assisted surgery, has seen its shares decline this year despite the rapid adoption of its latest da Vinci 5 system. With over 2,000 da Vinci 5 devices installed and fewer than 8% of eligible procedures currently robotic, the company has a significant growth runway. Features like Force Feedback Technology and future plans for telesurgery could further solidify its market position and drive long-term returns for investors.
Advertisement

Intuitive Surgical VP Fredrik Widman sells $407,765 in common stock

https://www.investing.com/news/insider-trading-news/intuitive-surgical-vp-fredrik-widman-sells-407765-in-common-stock-93CH-5028008
Intuitive Surgical VP Fredrik Widman sold 1,089 shares of company common stock for $407,765, while simultaneously acquiring the same number of shares through stock options for $102,932. These transactions, conducted under a Rule 10b5-1 trading plan, leave Mr. Widman with 1,026 directly held shares and 2,178 non-qualified stock options. The company's stock has since risen 18%, and analysts have revised earnings upwards, indicating strong confidence despite some recent price target reductions by RBC Capital and Mizuho.

Form 4 Intuitive Surgical Inc: Fredrik Widman (VP Corporate Controller) For: 15 September By Investing.com

https://in.investing.com/news/stock-market-news/form-4-intuitive-surgical-inc-fredrik-widman-vp-corporate-controller-for-15-september-93CH-5705349
This article from Investing.com reports on a Form 4 filing for Intuitive Surgical Inc., detailing a transaction by Fredrik Widman, the VP Corporate Controller, on September 15. The publication provides this insider trading information to its readership, indicating a notable event for the company's stock, ISRG.

Form 4 Intuitive Surgical Inc: Fredrik Widman (VP Corporate Controller) For: 15 September

https://ng.investing.com/news/stock-market-news/form-4-intuitive-surgical-inc-fredrik-widman-vp-corporate-controller-for-15-september-93CH-2808566
This article reports on a Form 4 filing for Intuitive Surgical Inc., indicating insider transaction activity by Fredrik Widman, the VP Corporate Controller, related to September 15. The brief piece highlights this specific regulatory disclosure concerning the company's stock, without providing further details on the nature of the transaction.

Intuitive Surgical VP Fredrik Widman sells $407,765 in common stock By Investing.com

https://ca.investing.com/news/stock-market-news/intuitive-surgical-vp-fredrik-widman-sells-407765-in-common-stock-93CH-4959252
Fredrik Widman, VP Corporate Controller at Intuitive Surgical Inc. (NASDAQ:ISRG), sold 1,089 shares of common stock for $407,765 on September 15, 2026, while also acquiring the same number of shares through stock options. The company's stock has since risen 18%, and InvestingPro analysis suggests it remains undervalued despite the recent sale. This comes amidst strong third-quarter revenue for Intuitive Surgical, though GAAP earnings were affected by a litigation settlement.

Intuitive Surgical VP Fredrik Widman sells $407,765 in common stock By Investing.com

https://ng.investing.com/news/stock-market-news/intuitive-surgical-vp-fredrik-widman-sells-407765-in-common-stock-93CH-2808565
Fredrik Widman, VP Corporate Controller at Intuitive Surgical Inc. (NASDAQ:ISRG), sold 1,089 shares of common stock for $407,765 on September 15, 2026, while simultaneously acquiring the same number of shares through stock options for $102,932. This transaction was conducted under a Rule 10b5-1 trading plan and leaves Mr. Widman with 1,026 direct shares and 2,178 non-qualified stock options. The article also notes that analysts have upwardly revised earnings expectations for Intuitive Surgical, despite recent price target reductions from some firms following Q3 results.
Advertisement

SBC: AI And Clinic Growth Support A Higher Fair Value

https://simplywall.st/community/narratives/us/healthcare/nasdaq-sbc/sbc-medical-group-holdings/at1lzccv-ai-and-new-medical-services-will-reshape-this-aesthetic-clinic-network-over-time/updates/2-analysts-have-raised-their-price-target-for-sbc-medical-grou
SBC Medical Group Holdings has seen its fair value price target raised to $9.25 from $8.25 due to updated financial assumptions, including higher revenue growth and future P/E levels. The company's third-quarter 2026 results showed significant revenue and EBITDA growth, supported by new clinic openings and strategic alliances with NeuroBrain Dynamics and AtomicSoftware Inc. to develop AI solutions for revenue expansion, cost reduction, and increased clinic productivity. SBC is also pursuing in-house AI development for biological age testing.

Form 4 Intuitive Surgical Inc: Gary Loeb (EVP & Chief Legal and Complian) For: 10 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-intuitive-surgical-inc-gary-loeb-evp--chief-legal-and-complian-for-10-november-93CH-5704960
This article reports on a Form 4 filing for Intuitive Surgical Inc., detailing a transaction involving Gary Loeb, EVP & Chief Legal and Compliance Officer, for November 10. The filing, published by Investing.com, indicates an insider transaction for the medical device company.

Intuitive Surgical EVP sells $183,260 in company stock By Investing.com

https://uk.investing.com/news/stock-market-news/intuitive-surgical-evp-sells-183260-in-company-stock-93CH-4982880
Gary Loeb, EVP at Intuitive Surgical Inc., sold 400 shares for $183,260 on November 10, 2026, as part of a pre-arranged trading plan. The stock, despite being down year-to-date, is considered undervalued by InvestingPro. This transaction follows a recent Q3 earnings report where Intuitive Surgical exceeded revenue expectations but missed on GAAP EPS due to a litigation settlement.

Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to "Buy"

https://www.marketbeat.com/instant-alerts/analyst-wall-street-zen-upgrades-zimmer-biomet-nyse-zbh-to-buy-2026-11-14/
Wall Street Zen has upgraded Zimmer Biomet (NYSE:ZBH) from a "hold" to a "buy" rating. Despite this upgrade, the broader analyst consensus for ZBH remains "hold" with an average price target of $112.74. The company recently exceeded quarterly earnings and revenue estimates, though insider sales have also been reported.

Vaneck Robotics ETF (IBOT) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/IBOT/latest-news/
The Vaneck Robotics ETF (IBOT) closed at $60.18, down 0.22%. Recent news highlights include analyst blogs featuring IBOT alongside other robotics-related stocks and ETFs like NVDA, ISRG, and BOTZ, discussing investment in the future of robotics. The ETF has shown strong year-to-date performance, returning +14.73%.
Advertisement

SBC Medical Group Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:e9a812cf9094b:0-sbc-medical-group-q3-earnings-call-highlights/
SBC Medical Group reported a strong fiscal third quarter with revenue up 35% to $59 million and operating income increasing by 66% to $26 million, driven by higher management service fees, rental revenue, and a new consolidated business. The company plans to expand its clinic network, invest in longevity services, artificial intelligence, and acquisitions, while also exploring expansion opportunities in the United States and Southeast Asia.

GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research

https://finance.yahoo.com/healthcare/articles/ge-healthcare-forms-magnus-neuro-153600071.html
GE HealthCare Technologies Inc. (GEHC) announced the formation of the MAGNUS Neuro Alliance, a research network dedicated to advancing neuroscience using its ultra-high-gradient, head-only 3.0T MR system. This alliance aims to foster collaboration among leading researchers and clinicians, exploring advanced MRI techniques and developing novel imaging biomarkers for neurological conditions. The initiative seeks to translate scientific breakthroughs into improved patient outcomes, with participating institutions including major universities and hospitals worldwide.

If You Invested $100 In Intuitive Surgical Stock 20 Years Ago, You Would Have This Much Today

https://www.benzinga.com/news/26/11/63238260/if-you-invested-100-intuitive-surgical-stock-20-years-ago-you-would-have-much-today
Intuitive Surgical (NASDAQ: ISRG) has significantly outperformed the market over the past two decades, achieving an average annual return of 20.31%. An initial investment of $100 in ISRG stock 20 years ago would now be worth $4,011.54. This highlights the substantial impact of compounded returns on investment growth over time.

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:9f00fe986094b:0-here-s-why-you-should-retain-dexcom-stock-in-your-portfolio-for-now/
DexCom (DXCM) is positioned for growth due to the potential of the continuous glucose monitoring (CGM) market, strong performance in 2026, and international expansion. Key drivers include the adoption of its G7 15 Day System, manufacturing efficiencies, a European direct distribution strategy, and Smart Basal technology. However, risks like PBM formulary changes, initial margin pressure from the Ireland facility ramp-up, and rising investment requirements could temper operating leverage.

SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion

https://www.stocktitan.net/news/SSII/ss-innovations-strengthens-management-team-in-preparation-for-global-pjlv5awlbiz2.html
SS Innovations International (NASDAQ: SSII) has appointed Dr. Vishwa Srivastava as President and Gary Lo as Chief Financial Officer to bolster its management team. These strategic leadership changes are part of the company's preparations for a planned global expansion of its SSi Mantra surgical robotic system, including efforts to secure FDA and CE marking certifications. SS Innovations also intends to launch a pipeline of new healthcare technologies, with development ongoing at its R&D facility in India.
Advertisement

Teleflex stock hits 52-week high at 156.75 USD

https://www.investing.com/news/company-news/teleflex-stock-hits-52week-high-at-15675-usd-93CH-5022252
Teleflex Inc (NYSE:TFX) has reached a new 52-week high of $156.75, reflecting a 29% year-to-date return and a 42.85% increase over the past year. InvestingPro analysis indicates the stock is still undervalued with a Fair Value of $186.80. This performance follows stronger-than-expected Q3 2026 results and analyst price target increases.

Here's Why You Should Retain AMN Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:e15112bb5094b:0-here-s-why-you-should-retain-amn-stock-in-your-portfolio-for-now/
AMN Healthcare Services, Inc. (AMN) is expected to grow due to strong demand in nurse and allied staffing, opportunities in Managed Services Programs (MSPs), and investments in technology. Despite these positives, the company faces headwinds from pricing pressure, competitive challenges, visa appointment delays for international nurses, and weakness in its Physician and Technology businesses. Analysts project significant earnings growth for 2026, and the stock has outperformed the industry year-to-date.

What Has The Market Missed In Intuitive Surgical Stock’s Drop?

https://www.trefis.com/stock/isrg/articles/624632/what-has-the-market-missed-in-intuitive-surgical-stocks-drop/2026-11-12
Intuitive Surgical's stock has dropped 22% over the past year despite a 30% rise in systems revenue in Q3 2026, driven by strong demand for its new da Vinci 5 surgical robot. The company's future performance will depend on whether the increased adoption of newer, richer product mix can offset anticipated instrument price cuts and a slowing U.S. procedure growth. Investors should closely watch da Vinci instrument and accessory revenue per procedure, which will be affected by these factors.

Under a trading plan, Gary Loeb sells 400 Intuitive Surgical (ISRG) shares at $458.15 each.

https://www.stocktitan.net/sec-filings/ISRG/form-4-intuitive-surgical-inc-insider-trading-activity-d89a5c2f5973.html
Intuitive Surgical officer Gary Loeb sold 400 shares of common stock at $458.15 per share on November 10, 2026, under a Rule 10b5-1 trading plan. After the sale, his direct holdings in the company were 6,236 shares. The transaction was formally reported on November 12, 2026.

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

https://www.tradingview.com/news/zacks:bcb1fc627094b:0-here-s-why-you-should-retain-conmed-stock-in-your-portfolio-for-now/
CONMED Corporation (CNMD) is recommended for retention in portfolios due to strong growth drivers such as the adoption of AirSeal, Buffalo Filter, and BioBrace platforms. The company benefits from rising robotic procedure volumes and expanding Ambulatory Surgery Centers, with its stock outperforming the industry and S&P 500. However, challenges include U.S. Orthopedic weakness, volatility in OEM Buffalo Filter sales, and less predictable international growth due to distributor order timing.
Advertisement

ISRG Agrees to $450M Settlement: What Does It Mean for Investors?

https://www.tradingview.com/news/zacks:fe47f5c0e094b:0-isrg-agrees-to-450m-settlement-what-does-it-mean-for-investors/
Intuitive Surgical (ISRG) reported a significant impact on its third-quarter 2026 earnings due to a $450 million litigation settlement concerning its da Vinci ecosystem. While the settlement negatively affected GAAP net income, the company still showed strong underlying operating performance with revenues increasing 22% and procedures growing 15%. This agreement is also seen as a strategic move to strengthen customer relationships and ensure clarity regarding third-party servicing and remanufacturing of instruments.

Intuitive Surgical, Inc. Tokenized Stock (Coinbase) price today, ISRGc to USD live price, marketcap and chart

https://coinmarketcap.com/currencies/intuitive-surgical-inc-tokenized-stock-coinbase/
This page from CoinMarketCap provides a preview of Intuitive Surgical, Inc. Tokenized Stock (Coinbase), identified by the ticker ISRGc. It details its total supply, circulating supply, contract address, and relevant tags like "Tokenized Assets" and "Tokenized Stock." The article also features trending real-world assets and most visited cryptocurrencies on the platform.

Nuclear Medicine’s Next Era: Preparing Medtech for the Rise of Precision Therapies

https://www.mpo-mag.com/exclusives/nuclear-medicines-next-era-preparing-medtech-for-the-rise-of-precision-therapies/
Nuclear medicine is entering a new era driven by advances in radiopharmaceuticals, imaging technologies, and theranostics, creating a convergence that reshapes disease detection and treatment. While innovation in precision radiopharmaceuticals is accelerating, the healthcare ecosystem, including medtech infrastructure, is struggling to keep pace, risking suboptimal utilization and limited patient access. Addressing this requires a holistic approach focused on adaptable hardware, quantitative software, integrated workflows, and reliable access to radiopharmaceuticals, demanding collaboration across all stakeholders to scale precision care effectively.

Intuitive Surgical (ISRG) Dropped, So What Is Driving Attention Now?

https://ca.finance.yahoo.com/news/intuitive-surgical-isrg-dropped-driving-091523790.html
Intuitive Surgical (ISRG) has seen choppy stock performance despite recent quarterly results showing 22% revenue growth and increased use of its da Vinci 5 and Ion systems, alongside a significant antitrust settlement charge. While one narrative suggests the stock is 29% undervalued due to its business model and patent moat, another view finds it expensive based on its high P/E ratio compared to industry averages. Investors are advised to conduct their own research given the split sentiment.

TELA Bio Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63127544/tela-bio-q3-2026-earnings-call-transcript
TELA Bio reported Q3 2026 revenue of $19 million, an 8% year-over-year decrease, despite sequential growth in U.S. hernia revenue and 18% growth in European revenue. The company implemented a $17 million cost reduction plan, improved its adjusted EBITDA loss by 55% sequentially, and regained Nasdaq compliance. Strategic shifts include a focus on high-ASP procedures, strengthened clinical validation with new publications, and FDA clearance for the Liora Monofilament Scaffold, aiming for a return to double-digit growth.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement